OTHER RELEVANT INFORMATION

Other relevant Information

GRIFOLS, S.A. guarantees that the texts published in this page correspond exactly and entirely with the texts sent to the CNMV by the Company or by third parties. All the communications are available in the Web page of the CNMV.

2023

Februar 24, 2023
Amendment of the Internal Regulations of the Board of Directors

Februar 21, 2023
Thomas Glanzmann new Grifols Executive Chairman, after Steven F. Mayer resignation

Februar 15, 2023
Grifols announces comprehensive operational improvement plan including EUR 400 million annualized cost savings initiative

2022

Oktober 21, 2022
Grifols' statement on articles published in certain Spanish media

Oktober 3, 2022
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson

September 26, 2022
Board of Directors communication in the context of considerable geopolitical uncertainty and market volatility

September 7, 2022
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada

Juli 28, 2022
Grifols sold MedKeeper to affiliates of the US company Becton Dickinson for US$ 93 million

Juni 10, 2022
Information on the resolutions approved at the General Meeting of Shareholders on June 10, 2022

Mai 6, 2022
Call notice of the General Shareholders' Meeting of Grifols, S.A. 2022

April 28, 2022
Grifols restates the consolidated annual accounts of the fiscal year 2021

April 25, 2022
Grifols completes the acquisition of Biotest

April 12, 2022
Grifols obtains all regulatory approvals to close the Biotest acquisition

Februar 28, 2022
Audit Committee and Sustainability Committee reorganization, as well as the appointment of the new Lead Independent Director of Board of Directors

2021

November 17, 2021
Grifols and GIC obtain authorization for their strategic agreement for USD 1 billion

Oktober 5, 2021
Grifols closes its EUR 2 billion bond issuance to finance its investment in Biotest

September 27, 2021
Grifols initiate the launch of a €2bn equivalent senior unsecured notes

August 16, 2021
Consent solicitation results on the lenders under Credit Agreement and the European Investment Bank to amend certain provisions of the senior debt

August 6, 2021
Consent solicitation results on Secured and Unsecured Notes to amend certain provisions of the senior debt

Juli 30, 2021
Commencing a consent solicitation to amend certain provisions of the senior debt

Juli 30, 2021
Grifols signs an agreement with ImmunoTek to open 21 plasma centers and further advances on its expansion plan

Juni 30, 2021
Grifols announces a strategic investment from GIC of USD 1 billion

Juni 14, 2021
Termination of the buyback programme

Juni 11, 2021
Recurring information under the buy-back programme of shares

Mai 31, 2021
Recurring information under the buy-back programme of shares

Mai 31, 2021
Information on the specific dividend payment conditions

Mai 25, 2021
Recurring information under the buy-back programme of shares

Mai 21, 2021
Information on the resolutions approved at the General Meeting of Shareholders on May 21, 2021

Mai 17, 2021
Recurring information under the buy-back programme of shares

Mai 10, 2021
Recurring information under the buy-back programme of shares

Mai 3, 2021
Recurring information under the buy-back programme of shares

April 26, 2021
Recurring information under the buy-back programme of shares

April 19, 2021
Recurring information under the buy-back programme of shares

April 16, 2021
Notice of Annual General Shareholders' Meeting 2021

April 12, 2021
Recurring information under the buy-back programme of shares

April 7, 2021
Grifols advances in the execution of its expansion plan with the acquisition of 7 plasma centers in the U.S.

April 6, 2021
Recurring information under the buy-back programme of shares

März 29, 2021
Recurring information under the buy-back programme of shares

März 22, 2021
Recurring information under the buy-back programme of shares

März 12, 2021
Buy-back plan of shares

März 9, 2021
Grifols reinforces its innovation strategy after completing the acquisition of GigaGen

März 1, 2021
Grifols acquires 25 U.S.-based plasma centers from BPL ensuring one million additional liters for fractionation

Februar 22, 2021
The Regulations of the Sustainability Committee

Januar 19, 2021
Grifols begins a new COVID-19 trial containing anti-SARS-CoV-2 polyclonal antibodies

2020

Dezember 16, 2020
Grifols amends certain articles of the Regulations of the Board of Directors and creates a Sustainability Committee

Dezember 15, 2020
Grifols closes the acquisition of Alkahest

November 24, 2020
Grifols strategically expands its operations into Egypt

November 9, 2020
Grifols acquires the remaining 49% of MedKeeper

Oktober 9, 2020
Information on the resolutions approved at the General Meeting of Shareholders on October 9, 2020

Oktober 1, 2020
Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.

September 7, 2020
Grifols continues strengthening its innovation strategy with the acquisition of Alkahest

September 4, 2020
Notice of Annual General Shareholders' Meeting 2020

Juli 20, 2020
Grifols to acquire Green Cross plasma fractionation facility in Montreal and a plasma collection organization in the U.S. for US$460 million

Mai 7, 2020
Grifols reinforces its liquidity position to EUR 1,700 million

Februar 18, 2020
Grifols and the Public Investment Fund of Saudi Arabia to boost plasma medicines self-supply in the region

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.